Agenus to Participate in Two Upcoming Investor Conferences
September 02 2014 - 7:00AM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company
developing a portfolio of checkpoint modulators (CPMs), heat shock
protein peptide-based vaccines, and adjuvants, today announced that
Garo Armen, PhD, Chief Executive Officer, and Robert Stein, MD,
PhD, Chief Scientific Officer, will conduct a series of one-on-one
meetings with investors at the FBR Inaugural Healthcare Conference
on Wednesday, September 3 in Boston.
Agenus management will also present a Company overview at the
Rodman & Renshaw 16th Annual Healthcare Conference in New York
City on Tuesday, September 9 at 9:10 a.m. EDT.
Webcast Information
The live and archived webcast of the presentation will be
accessible from the Company’s website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before each event to
ensure a timely connection. The archived replay will be available
on the Agenus website for one month following the conference.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein vaccines and
adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40,
LAG-3, TIM-3, CTLA-4 and PD-1, critical targets in co-stimulatory
and inhibitory pathways regulating self-tolerance and immune
responses to tumor antigens. Checkpoint modulators represent an
important new class of cancer immunotherapeutics. The Company’s
proprietary discovery engine, Retrocyte Display,® is used to
generate fully human and humanized therapeutic antibody drug
candidates. The Retrocyte Display platform uses IgG format human
antibody libraries expressed in mammalian B-lineage cells, to
generate antibodies with high potency and specificity, and with no
re-engineering requirement. Agenus’ Prophage heat shock protein
vaccines recently generated positive data in phase 2 studies in
newly diagnosed gliobastoma (the most common and most aggressive
malignant primary brain cancer) and in genital herpes (an incurable
infectious disease afflicting over 40 million adults in the United
States). The Company’s QS-21 Stimulon® adjuvant is a key component
in the development of several investigational vaccines across a
wide variety of infectious diseases, and therapeutic vaccines
intended to treat cancer and degenerative disorders. The QS-21
platform is extensively partnered with GlaxoSmithKline and Janssen
and includes two candidates in phase 3 trials for melanoma and
shingles. A regulatory application was filed recently by
GlaxoSmithKline with the EMA, and has been accepted for review,
following positive results in a phase 3 trial in malaria. For more
information, please visit www.agenusbio.com, or connect with the
company on Facebook, LinkedIn, Twitter and Google+. For more
information, please visit www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding the Company’s upcoming corporate
presentation. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission for the period ended June 30, 2014. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus
undertakes no obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Agenus’ business is subject
to substantial risks and uncertainties, including those identified
above. When evaluating Agenus’ business and securities, investors
should give careful consideration to these risks and
uncertainties.
BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024